Johnson RK - Search Results

1

In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells.

Mattern MR, Hofmann GA, Polsky RM, Funk LR, McCabe FL, Johnson RK. Mattern MR, et al. Among authors: johnson rk. Oncol Res. 1993;5(12):467-74. Oncol Res. 1993. PMID: 8086668

2

Pharmacological activities of spirogermanium and other structurally related azaspiranes: effects on tumor cell and macrophage functions.

Mirabelli CK, Badger AM, Sung CP, Hillegass L, Sung CM, Johnson RK, Picker D, Schwartz D, Dorman J, Martellucci S. Mirabelli CK, et al. Among authors: johnson rk. Anticancer Drug Des. 1989 Mar;3(4):231-42. Anticancer Drug Des. 1989. PMID: 2930625

3

Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity.

Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallagher G, Caranfa MJ, McCabe FL, Faucette LF, Johnson RK, et al. Kingsbury WD, et al. Among authors: johnson rk. J Med Chem. 1991 Jan;34(1):98-107. doi: 10.1021/jm00105a017. J Med Chem. 1991. PMID: 1846923

4

Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864).

Mattern MR, Hofmann GA, McCabe FL, Johnson RK. Mattern MR, et al. Among authors: johnson rk. Cancer Res. 1991 Nov 1;51(21):5813-6. Cancer Res. 1991. PMID: 1657371

5

Antagonism of TGF-alpha receptor binding and TGF-alpha induced stimulation of cell proliferation by methyl pheophorbides.

Rieman DJ, Anzano MA, Chan GW, Imburgia TJ, Chan JA, Johnson RK, Greig RG. Rieman DJ, et al. Among authors: johnson rk. Oncol Res. 1992;4(4-5):193-200. Oncol Res. 1992. PMID: 1324032

6

Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content.

Woessner RD, Eng WK, Hofmann GA, Rieman DJ, McCabe FL, Hertzberg RP, Mattern MR, Tan KB, Johnson RK. Woessner RD, et al. Among authors: johnson rk. Oncol Res. 1992;4(11-12):481-8. Oncol Res. 1992. PMID: 1338578

7

In vivo development and in vitro characterization of a subclone of murine P388 leukemia resistant to bis(diphenylphosphine)ethane.

Hoke GD, McCabe FL, Faucette LF, Bartus JO, Sung CM, Jensen BD, Heys JR, Rush GF, Alberts DW, Johnson RK, et al. Hoke GD, et al. Among authors: johnson rk. Mol Pharmacol. 1991 Jan;39(1):90-7. Mol Pharmacol. 1991. PMID: 1898982

8

Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.

Tan KB, Mattern MR, Eng WK, McCabe FL, Johnson RK. Tan KB, et al. Among authors: johnson rk. J Natl Cancer Inst. 1989 Nov 15;81(22):1732-5. doi: 10.1093/jnci/81.22.1732. J Natl Cancer Inst. 1989. PMID: 2553992

9

Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.

Eng WK, McCabe FL, Tan KB, Mattern MR, Hofmann GA, Woessner RD, Hertzberg RP, Johnson RK. Eng WK, et al. Among authors: johnson rk. Mol Pharmacol. 1990 Oct;38(4):471-80. Mol Pharmacol. 1990. PMID: 2172765

10

Irreversible trapping of the DNA-topoisomerase I covalent complex. Affinity labeling of the camptothecin binding site.

Hertzberg RP, Busby RW, Caranfa MJ, Holden KG, Johnson RK, Hecht SM, Kingsbury WD. Hertzberg RP, et al. Among authors: johnson rk. J Biol Chem. 1990 Nov 5;265(31):19287-95. J Biol Chem. 1990. PMID: 2172250

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results